A consolidated read on what the data shows across both independent trusts — financial, clinical, and strategic.
Combined plan savings identified across Trust 1 (28.3%) and Trust 2 (37.9%), reflecting meaningful employer cost reduction without disrupting member access.
Total member savings observed in the dataset. RxProtect's alternative acquisition pathway materially increases — and frequently delivers — point-of-dispense member savings for high-impact medications.
A small concentrated group of specialty and brand medications producing 30%+ savings drives the majority of the financial opportunity across both trusts.
It is a pharmacy optimization platform that identifies targeted opportunities where alternative acquisition pathways outperform traditional pharmacy purchasing.
The analysis demonstrates that a relatively small number of high-cost specialty medications create the majority of available savings. Even after considering average market rebates, many opportunities remain well beyond what traditional PBM contracting alone can typically achieve.
The result is meaningful employer savings while simultaneously improving member affordability and medication access.